Allena Pharmaceuticals, Inc. EV/EBITDA

EV/EBITDA of ALNA for past 10 years: annual, quarterly and twelve month trailing (TTM) including EV/EBITDA growth rates and interactive chart. EV/EBITDA is a ratio that compares a company’s Enterprise Value (EV) to its Earnings Before Interest, Taxes, Depreciation & Amortization (EBITDA). The EV/EBITDA ratio is a valuation metric used to compare the relative value of different businesses. A low EV/EBITDA compared to a stock’s historical average or industry can indicate undervaluation.


Highlights and Quick Summary

Visit stockrow.com/ALNA for comprehensive keystats, realtime prices, income statement, balance sheet, cash flow statement with 10 years of data, and state-of-the-art screener.

Historical EV/EBITDA of Allena Pharmaceuticals, Inc.

Most recent EV/EBITDAof ALNA including historical data for past 10 years.

Interactive Chart of EV/EBITDA of Allena Pharmaceuticals, Inc.


Business Profile of Allena Pharmaceuticals, Inc.

Sector: Healthcare
Industry: Biotechnology
Allena Pharmaceuticals, Inc., a biopharmaceutical company, discovers, develops, and commercializes oral enzyme therapeutics to treat patients with rare and severe metabolic, and kidney disorders in the United States. Its lead product candidate is ALLN-346, a novel and urate degrading enzyme for patients with hyperuricemia and gout in the setting of advanced chronic kidney disease. The company was incorporated in 2011 and is headquartered in Newton, Massachusetts.